ArticleTranslational cancer research2026
A pneumolysin mutant (ΔA146 ply) induces pyroptosis in triple-negative and HER2-positive breast cancer cells via the Caspase-1/GSDME pathway: a potential antibody-drug conjugate payload.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The success of antibody-drug conjugates (ADCs) relies on potent cytotoxic payloads. Discovery of novel toxins that induce immunogenic cell death (such as pyroptosis) holds promise for overcoming tumor heterogeneity and enhancing anti-tumor immunity. Pneumolysin (Ply) is a pore-forming toxin from Streptococcus pneumoniae, but its wild-type form is overly toxic. Here we investigate the potential of a detoxified mutant, ΔA146 ply, to induce pyroptosis in triple‑negative (MDA‑MB‑231) and human epidermal growth factor receptor 2 (HER2)‑positive (MDA‑MB‑453) breast cancer cells, using a cell-penetrating peptide (CPP) fusion to facilitate cellular entry for in vitro evaluation of its activity as a candidate ADC payload. Methods: A flexible peptide linker was used to fuse ΔA146 ply with a CPP to facilitate cellular uptake, and the fusion gene was cloned into the pET‑21a(+) prokaryotic expression vector. The recombinant fusion protein was expressed in E. coli and purified by affinity chromatography. Cellular internalization was assessed by immunofluorescence using FITC-labeled protein. Cell death modalities were evaluated by lactate dehydrogenase (LDH) release assay, SYTOX Green staining, and morphological observation. Western blotting was performed to detect the cleavage of the pyroptosis executioner gasdermin E (GSDME). Caspase-1 activity was measured in cell lysates, and the release of inflammatory factors [interleukin‑1β (IL‑1β), interleukin‑18 (IL‑18), and high mobility group box 1 (HMGB1)] in the cell supernatant was determined. Results: High-purity recombinant ΔA146 ply-CPP was successfully obtained. The protein efficiently entered MDA-MB-231 and MDA-MB-453 cells. ΔA146 ply-treated cells displayed typical pyroptotic morphology (cell swelling, large bubble-like protrusions), significantly increased LDH release, and positive SYTOX Green staining. Mechanistically, ΔA146 ply markedly activated Caspase-1, induced GSDME cleavage, and promoted the release of IL-1β, IL-18, and HMGB1. Similar effects were observed in both cell lines, with no qualitative difference in the pyroptotic mechanism. Conclusions: ΔA146 ply triggers pyroptosis in breast cancer cells through the Caspase-1-mediated GSDME pathway. As a payload with immunostimulatory potential, it warrants further development for ADC applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.